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PA 2-Step Mechanism of Arterial Thrombus
Formation Induced by Human Atherosclerotic Plaques
Armin J. Reininger, MD, PHD,* Isabell Bernlochner, MD,† Sandra M. Penz, PHD,†
Catherine Ravanat, PHD,‡ Peter Smethurst, PHD,§ Richard W. Farndale, PHD,§
Christian Gachet, MD, PHD,‡ Richard Brandl, MD, Wolfgang Siess, MD†
Munich, Germany; Strasbourg, France; and Cambridge, United Kingdom
Objectives The aim of this study was to understand the initial mechanism of arterial thrombus formation induced by vulner-
able human atherosclerotic plaques to re-assess and improve current antithrombotic strategies.
Background Rupture of atherosclerotic plaques causes arterial thrombus formation that might lead to myocardial infarction and
ischemic stroke. Atherothrombosis is considered as an inseparable tangle of platelet activation and coagulation pro-
cesses, involving plaque components such as tissue factor (TF) and collagen as well as blood-borne TF and coagula-
tion factor XIIa (FXIIa). A combination of anticoagulants and antiplatelet agents is the present treatment.
Methods Human atheromatous plaque material was exposed to blood or blood components at physiological calcium/magne-
sium concentration. Platelet aggregation and coagulation were measured under static and arterial flow conditions by
state-of-the-art microscopic and physiological techniques. Plaque TF, plaque collagen, FXIIa, and platelet glycoprotein
VI (GPVI) were specifically inhibited.
Results Plaques induced thrombus formation by 2 discrete steps. The rapid first phase of GPVI-mediated platelet adhesion
and aggregation onto plaque collagen occurred within 1 min. The second phase of coagulation started after a delay
of 3 min with the formation of thrombin and fibrin, and was driven entirely by plaque TF. Coagulation occurred only
in flow niches provided by platelet aggregates, with no evidence for a role of blood-borne TF and FXIIa. Inhibition of
GPVI but not plaque TF inhibited plaque-induced thrombus formation.
Conclusions The major thrombogenic plaque components—collagen and TF—induce platelet activation and coagulation, respec-
tively, in 2 consecutive steps. Targeting specifically the first step is crucial and might be sufficient to inhibit athero-
thrombus formation. (J Am Coll Cardiol 2010;55:1147–58) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.051r
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aupture of vulnerable atherosclerotic plaques causes throm-
us formation leading to acute myocardial infarction, isch-
mic stroke, and peripheral arterial occlusive disease (1–4).
rterial thrombus formation after plaque rupture is consid-
red as reciprocally-amplifying, inseparable processes of
latelet activation and coagulation (5). Optimal treatment
rom the *Department of Transfusion Medicine and Hemostaseology, Clinic of
naesthesiology, University Clinic Munich, Munich, Germany; †Institute for Pre-
ention of Cardiovascular Diseases, University Clinic Munich, Munich, Germany;
INSERM UMR-S949, EFS-Alsace, Université de Strasbourg, Strasbourg, France;
Department of Biochemistry, University of Cambridge, Cambridge, United King-
om; and the Department of Vascular Surgery, Clinic Schwabing, Munich,
ermany. This work was supported by the Graduate Program GRK 438 “Vascular
iology in Medicine” (Dr. Bernlochner), grants from the Hella-Langer-Stiftung (Dr.
enz), the Friedrich-Baur-Stiftung, the August-Lenz-Stiftung, the British Heart
oundation (Drs. Smethurst and Farndale), and the Deutsche Forschungsgemein-
chaft (Si 274/9-3). The results are part of the doctoral thesis of Dr. Bernlochner, at
he University of Munich. Drs. Reininger and Bernlochner contributed equally to this
ork.t
Manuscript received August 5, 2009; revised manuscript received November 9,
009, accepted November 18, 2009.equires a combination of anticoagulants and antiplatelet
gents with the profound negative prospect of bleeding risk
n these patients (6–8).
Systemic and local factors are critical for atherothrombosis.
atients with cardiovascular disease often have increased plate-
et reactivity and coagulation (9,10), and pro-thrombotic sub-
tances are present in human atherosclerotic plaques that are
ot found in the intima of healthy arteries (11–14). Abundant
vidence exists that a main pro-thrombotic substance in human
therosclerotic plaque is tissue factor (TF), which is expressed
n apoptosis-derived microparticles and present mainly in the
ipid-rich core (3,15). Tissue factor—through the formation of
hrombin—induces platelet activation and stimulates fibrin
ormation. In lipid-rich human atherosclerotic plaques, direct
latelet agonists have also been identified: lysophosphatidic
cid mediating platelet shape change, and morphologically
iverse collagen type I and type III structures inducing platelet
dhesion and aggregation under arterial flow through binding
o platelet collagen receptors, including glycoprotein VI
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lebrand factor has an essential role
in mediating platelet adhesion to
collagen fibers and atherosclerotic
plaques and supporting subsequent
platelet aggregation on these ma-
trixes at high shear conditions
(11,18).
The formation of a thrombus
after plaque rupture is triggered
by thrombogenic plaque sub-
stances that set in motion an
avalanche of aggregating plate-
ets and fibrin strand formation, growing and accelerating as
t proceeds. We reasoned that identifying the critical trig-
er(s) of plaque-induced thrombus formation will improve
urrent antithrombotic strategies, which are so far directed
ainly against the avalanche itself, i.e., platelets (fibrinogen
eceptor antagonists) with their positive feedback activation
oops (aspirin, P2Y12 antagonists) and thrombin (heparins,
ivalirudin) but not their triggers.
In the present investigation, we studied atheromatous
uman plaques, exposed them to blood and blood compo-
ents, and applied and optimized state-of-the-art micro-
copic and physiological techniques. We studied the kinetics
f atherothrombosis and addressed the following main
uestions: 1) Is plaque TF—through the formation of
hrombin—involved in plaque-induced platelet adhesion
nd aggregation? 2) Is collagenous matrix of plaques—via its
ctivation of platelets and/or coagulation factor XII
FXII)—involved in plaque-induced thrombin and fibrin
ormation? We obtained a surprisingly simple answer to
hese questions: mainly that plaque collagen induces platelet
dhesion and aggregation, whereas plaque TF induces blood
oagulation.
ethods
eagents and antibodies. Collagen (Horm) was obtained
rom Nycomed Pharma (Munich, Germany). Sodium ci-
rate was from Fresenius Kabi Deutschland (Bad Homburg,
ermany); heparin, Triton X-100, bovine serum albumin
essentially fatty acid free), mepacrine, and collagenase (type
II from Clostridium histolyticum) as well as mouse immu-
oglobulin G (IgG)1 and rabbit IgG were obtained from
igma (Taufkirchen, Germany). Glutaraldehyde was pur-
hased from Serva, (Heidelberg, Germany). The GPVI
eceptor blocking single-chain variable fragment antibody
0B12 and its control 2D4 (anti-HLA type A2) was
elected from the Cambridge Antibody Technology (now
edImmune Cambridge, Cambridge, United Kingdom)
hage display libraries as described previously (19). Anti-
ollagen type I and anti-collagen type III antibodies were
btained from Rockland Immunochemicals (Gilbertsville,
ennsylvania). Anti-TF antibody was purchased from
Abbreviations
and Acronyms
CTI  corn trypsin inhibitor
FXII  coagulation factor
XII
GPVI  glycoprotein VI
PFP  platelet-free plasma
PPP  platelet-poor plasma
PRP  platelet-rich plasma
TF  tissue factormerican Diagnostica (Pfungstadt, Germany); corn trypsin cnhibitor (CTI) was purchased from Calbiochem (San
iego, California), and lipidated TF (Recombiplastin) was
urchased from Instrumentation Laboratory (Kirchheim,
ermany). For thrombin generation assays the fluorogenic
ubstrate Z-GGR-AMC (Bachem, Bubendorf, Switzer-
and) was dissolved to a concentration of 5 mmol/l in buffer
ontaining 10% dimethyl sulfoxide; as buffer we used
0-mmol/l HEPES, 150-mmol/l sodium chloride, with
0-mg/ml bovine serum albumin (Lot A-7030, Sigma,
aufkirchen, Germany), pH 7.35.
uman atheromatous plaques. Atherosclerotic plaques
ere obtained from patients who underwent endarterec-
omy of the carotid artery with en bloc preservation of the
issue structure (20). Patient consent was obtained and
pproved by the Ethics Committee of the Faculty of
edicine of the University of Munich. Plaque specimens
ere immediately shock frozen at 80°C after surgical
emoval. The atheromatous plaques macroscopically visible
y their yellowish color were dissected under sterile condi-
ions from other regions of the atherosclerotic tissue (21).
alcified plaques were discarded. The plaques were charac-
erized by histological analysis as atheroma with a thin
brous capsule (17,18,22). They were homogenized and
rocessed as described (17,18). The plaque concentration
as adjusted to 100 mg wet weight/ml. Plaques were
btained from a total of 45 patients.
laque collagen and TF localization. The collagen im-
unostaining of paraffin sections of atheromatous plaques
nd of plaque homogenates was done as described
17,18,20). For TF-immunostaining of plaque tissue sec-
ions and homogenates, an anti-TF antibody (No. 4509,
merican Diagnostica) was used. Immunfluorescence mi-
roscopy was performed with a Zeiss confocal fluorescence
icroscope (LSM510 META) and software.
lood sampling and platelet preparation. In accordance
ith the Helsinki protocol, informed consent was ob-
ained from healthy blood donors that had not taken any
latelet- or coagulation-relevant medication 14 days be-
ore blood-drawing. Platelet-rich plasma (PRP) was pre-
ared from citrate (0.313% wt/vol final concentration)
nticoagulated blood by centrifugation for 20 min at 180 g. For
latelet-poor plasma (PPP) the PRP was additionally cen-
rifuged for 10 min at 1,000 g. For platelet-free plasma
PFP) the PRP was centrifuged for 5 min at 4°C and at
,000 g, and subsequently the supernatant was centrifuged
t 10,000 g.
latelet aggregation and blood coagulation in whole
lood and PRP. Platelet aggregation stimulated by colla-
en, atheromatous plaque, or TF was measured turbidimet-
ically with stirred PRP (1,100 rpm) at 37°C in a LABOR
ggregometer (Fa. Fresenius, Bad Homburg, Germany) or
easured via impedance in stirred (1,000 rpm) diluted
lood by using the Multiplate system (Dynabyte Medical,
unich, Germany) as described by our group recently (23).
alcium chloride (CaCl2) (12 mmol/l) and magnesiumhloride (MgCl2) (0.1 mmol/l) were added to obtain phys-
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March 16, 2010:1147–58 Initial Steps of Atherothrombosisological plasma concentration of these divalent cations, and
o observe clotting. The concentration of calcium (Ca2)
as 1.23  0.08 mmol/l and that of magnesium (Mg2)
as 0.51  0.23 mmol/l (n  5) as measured with the
lectrolyte analyzer CRT-8 (Nova Biomedical, Roeder-
ark, Germany). Recombinant lipidated TF showed dose-
ependent (0.05 to 1.00 ng/ml) clotting under these con-
itions. Clotting was detected in both aggregometers as a
udden vertical deflection in the aggregation curve.
The kinetics of fibrin formation was also determined by
hrombelastography (Rotem, Pentapharm GmbH, Munich,
ermany).
hrombin generation in human PRP and PFP. Mea-
urements of thrombin generation with the Thrombogram
ethod (24) were performed with a ThermoLabsystems
scent reader (Helsinki, Finland) coupled to the Throm-
inoscope software developed by Synapse (Utrecht, the
etherlands). Collagen, TF, or atheromatous plaque was
ncubated together with human PRP (300,000 platelets/l)
r PFP and buffer (20-mmol/l HEPES, 5-g/l bovine serum
lbumin, 0.14-mol/l sodium chloride, 0.6-mmol/l MgCl2,
H 7.35). Thrombin measurement was started through the
ddition of fluo buffer (20-mmol/l HEPES, 60-mg/ml
ovine serum albumin, pH 7.35) containing the fluorescent
hrombin substrate Z-GGR-AMC (400 mol/l) and CaCl2
12 mmol/l). Measurements were performed in triplicate.
nhibition of plaque TF and collagen-platelet GPVI
nteractions. Plaque (0.5 mg) was incubated with polyclonal
nti-TF antibody (1 g) for 10 min at 37°C or rabbit IgG as
ontrol. Plaque collagens type I and III were blocked with
pecific polyclonal antibodies (0.5 g/l), again with rabbit
gG as control. To disrupt the collagenous structures in the
laque, atheromatous plaque (2 mg/ml) was incubated for 24 h
t 37°C with collagenase (0.6 g) dissolved in 50 l TESCA
uffer (50-mmol/l TES, N-Tris[hydroxymethyl]methyl-2-
mino-ethan-sulfonic acid, 0.36-mmol/l CaCl2) containing in
ddition 9-mmol/l CaCl2. Control incubations were with
ESCA buffer plus 9 mmol/l CaCl2 alone. Platelet GPVI
eceptor was inhibited by anti GPVI–single-chain variable
ragment 10B12 (50 g/ml) or control (anti-HLA type A2)
19).
nalysis of platelet adhesion and thrombus formation in
owing whole blood. Atheromatous plaque homogenate
as immobilized onto glass coverslips as described
17,18,21). The height of the plaque coating was 5 m.
lass coverslips were also coated with 30 l of lipidated TF
0.3 g/ml and 0.9 g/ml) and fibrous collagen (5 g/ml).
he coated surfaces were perfused (syringe pump; Harvard
pparatus, Holliston, Massachusetts) with citrated blood
fter addition of CaCl2 and MgCl2 in a parallel plate flow
hamber at a wall shear rate of 1,500 s1. The chamber was
ounted on the stage of an upright microscope (Axioscope
plus, Carl Zeiss, Germany), and blood flow and platelet
eposition were observed and recorded in real-time with a
CD camera (AVT-BT 71, AVT Horn, Aalen, Germany)nd a DVD video recorder (Panasonic, LQ-MD 800, AVT worn). We used bright field and reflection interference
ontrast microscopy. Both required no labeling of platelets,
hereas for fluorescence microscopy the platelets were
tained with 10-mol/l mepacrine. Reflection interference
ontrast microscopy allowed us to visualize platelet spread-
ng. By combining bright field microscopy and fluorescence
icroscopy, platelet adhesion and aggregation could be
iscerned from the plaque coating. During each flow exper-
ment, representative images (fields of view) of the perfused
urface were recorded and later digitized and analyzed
ff-line with the Matrox Inspector software package (Ma-
rox Electronics Systems, Ltd., Dorval, Quebec, Canada).
n each field the areas covered by plaques and the respective
ggregates attached to them were measured and related as
ercentage “plaque covered with platelet aggregates.” Single
latelet adhesion was easily discernible and was not included
n the measurements. Online Video 1 was prepared with
dobe Premiere (Adobe Systems, San Jose, California).
tatistical analysis. Results are shown as mean SD from
experiments. Statistical significance was calculated by
aired and unpaired Student t test or Mann-Whitney U
est, where appropriate. Differences were considered signif-
cant when p (2-tailed test) was 0.05.
esults
haracterization of collagen type III-positive matrix
tructures and TF in atheromatous plaques. Atheroma-
ous plaques containing both lipid-rich core and capsule
ere used in the present study. Figure 1A shows represen-
ative light micrographs of plaque sections after staining
ith specific anti-collagen type III and anti-TF antibodies.
t is seen that TF-positive structures and collagenous matrix
re not colocalized. The TF was mainly found in macro-
hages, foam cells, and smooth muscle cells in the fibrous
ap, often at the transition from cap to core. Endothelial
ells were TF-negative.
Plaque homogenates containing all potential thrombo-
enic substances were used for further experimentation.
igure 1B shows fluorescence micrographs of plaque ho-
ogenates after coating onto glass coverslips and staining
ith specific anti-collagen type III and anti-TF antibodies.
t can be seen that the plaque homogenates contained lipids
nd matrix (autofluorescence), heterogeneous collagen type
II-positive matrix particles, and TF.
Biochemical experiments showed TF activity in the
theromatous plaques from all patients. The mean clot
ormation time in recalcified PPP induced by plaque
omogenate (1.6 mg) was 9.2  4.4 min (n  9 plaques),
imilar to that observed with 0.1-ng lipidated recombi-
ant TF (9.8  3.9 min; n  9). In plaques from some
atients only the lipid-rich core was obtained; the clot-
ing activity of this material was lower (clot formation
ime 15.2  0.44 min; n  3). Blockade of TF by
re-incubating the whole plaques or the lipid-rich core
ith a specific anti-TF antibody drastically prolonged the
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Initial Steps of Atherothrombosis March 16, 2010:1147–58laque-induced clotting times in PPP to 21  3.9 min (n
10), close to control values in the absence of plaque
25 min). Together these results show that TF is present in
he fibrous cap and lipid core of the plaques studied and that
F is the main determinant of clotting in PPP. The mean
oncentration of active TF in atheromatous plaques was
alculated as 62 pg/mg, which is similar to the TF antigen
ontent described in the literature in atherectomy samples of
uman coronary atherosclerotic plaques (range 0.03 to 0.05 ng
F/mg wet weight) (25) and to our own immunoblot data
ith anti-TF antibody (data not shown).
inetics of plaque-induced platelet aggregation and clot
ormation under static conditions: comparison with
ollagen and TF. In citrated PRP re-adjusted to physio-
ogical Ca2 and Mg2 concentrations, both plaque and
ollagen induced platelet shape change and aggregation first
within the first 1 min) and then clotting—after a delay of
everal minutes. Both platelet stimuli caused almost identi-
al platelet aggregation in PRP with regard to kinetics and
eak amplitude, reached after 2 to 3 min. Coagulation was
bserved after maximal platelet aggregation (Fig. 1A). The
Figure 1 Localization of Collagen and TF in Atheromatous Plaq
(A) In situ collagen type III and tissue factor (TF) immunostaining (brown) in sectio
coated on glass cover slips were analyzed by confocal immunofluorescence micros
nm), and matrix (green; excitation 488 nm; emission 505 to 530 nm); middle: sta
(green) and autofluorescence of plaque lipids (red).ag times of clotting stimulated with plaque and collagen pere similar (4.7 0.9 min and 5.9 1.1 min, respectively;
 6, p  0.05). Recombinant lipidated TF induced
latelet aggregation only in the presence of Ca2 and Mg2
ollowed immediately by clotting (Fig. 2A). Spontaneous
lotting of Ca2-readjusted and Mg2-readjusted PRP
tarted after 15  4 min (n  4).
In whole blood with reconstituted Ca2 and Mg2,
latelet aggregation after plaque and collagen stimulation
lso occurred before clot formation. Clot formation started
t 3.8 1.3 min (n 5) with plaque stimulation and 4.7 
.5 min (n  7) with collagen stimulation (Fig. 2B).
echanism of plaque-induced platelet aggregation. Plaque-
nduced platelet aggregation was completely dependent on
he interaction of collagenous plaque structures with platelet
PVI as observed previously after plaque-stimulation of
solated platelets or platelets in anticoagulated blood (17). It
as completely prevented by: 1) pre-treatment of plaques
ith either collagenase or a GPVI-Fc fusion protein or
nti-collagen type I and type III antibodies; or 2) incubation
f PRP with anti-GPVI antibodies (Fig. 3A) (and data not
hown). After blockade of platelet GPVI the kinetics of
an atheromatous plaque from human carotid artery. (B) Plaque homogenates
Left, autofluorescence (merge): lipids (red; excitation 543 nm; emission 560
ith anti-collagen type III antibody (AB) (green); right: staining with anti-TF ABues
ns of
copy.
ining wlaque-induced aggregation and clotting resembled the
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March 16, 2010:1147–58 Initial Steps of Atherothrombosisattern observed after stimulation with TF (Fig. 2A).
oreover, inhibition of thrombin with hirudin or inhibition
f plaque TF did not affect plaque-stimulated aggregation
Figure 2 Comparison of Plaque-, Collagen-, and TF-Induced Plat
(A) Stimulation of platelet-rich plasma (PRP); shown are representative aggregatio
gen (2.5 g/ml), or tissue factor (TF) (0.1 and 0.5 ng/ml) before and after additio
Clot formation is indicated by a sudden vertical deflection of the tracing. (B) Stimu
(0.42 mg wet weight/ml) and collagen-induced (2.5 g/ml) platelet aggregation in
(middle), and citrated blood containing in addition 32 g/ml corn trypsin inhibitorf PRP and blood (see the following text). These results Gndicate that the rapid first phase of plaque-mediated
latelet aggregation is mediated by interaction of collage-
ous type I and type III plaque structures with platelet
Aggregation and Clot Formation
ngs (n  6) of citrated PRP stimulated by plaque (1.25 mg wet weight/ml), colla-
2 mmol/l calcium chloride (CaCl2) and 0.1 mmol/l magnesium chloride (MgCl2).
of blood; shown are representative impedance aggregation tracings of plaque-
d blood (left), citrated blood containing 8 mmol/l CaCl2 and 0.1 mmol/l MgCl2
o block intrinsic coagulation (right).elet
n traci
n of 1
lation
citrate
(CTI) tPVI and not by locally generated thrombin.
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Initial Steps of Atherothrombosis March 16, 2010:1147–58echanism of plaque-induced thrombin and fibrin formation.
e pre-incubated plaque homogenates with a polyclonal
nti-TF antibody in a concentration sufficient to block
lotting triggered by 0.5 ng/ml TF. Such inhibition of
laque TF had no effect on platelet aggregation but pro-
onged clotting time from 5.7  1.6 min to 10  1.6 min
n PRP (n  4, p  0.003) (Fig. 3B).
Similarly, in whole blood, pre-incubation of plaque with
specific anti-TF antibody delayed plaque-stimulated co-
gulation from 4.2 0.5 min (plaque rabbit IgG control)
o 10.5  2.6 min (n  3; p  0.05) but had no effect on
latelet aggregation (Fig. 3C) (data not shown). Thus,
laque TF seemed to be crucial for coagulation but not for
Figure 3 Plaque Collagen/Platelet GPVI Interaction Induces Pl
(A) Plaque-induced platelet aggregation is mediated by interaction of collagenous
nase, or PRP was pretreated with the anti-GPVI antibody; 12 mmol/l CaCl2 and 0.1
PRP) stimulation. Representative tracings of 3 experiments are shown. (B) Plaque
homogenate (5 l) was pretreated with rabbit immunoglobulin G (IgG) (4 g) or an
mmol/l) were added before plaque stimulation (1.25 mg wet weight/ml PRP). Rep
induced coagulation but not platelet aggregation in blood is mediated by plaque TF
(0.83 mg wet weight/ml blood) and TF (0.1 ng/ml) to citrated blood containing 32
for 10 min at 37°C with control rabbit IgG (4 g) or anti-TF antibody (4 g). Abbrevlatelet aggregation in both PRP and blood. TNext, the kinetics and quantity of thrombin formation was
easured in PRP and PFP stimulated by plaque, TF, and
ollagen (Fig. 4). We used a final concentration of recombinant
ipidated TF of 0.1 ng/ml, corresponding to our determina-
ions of plaque TF (see preceding text). Pre-incubation of
laque or TF with an anti-TF antibody significantly delayed
he lag time and time to peak of thrombin formation in PRP
fter stimulation (Figs. 4A and 4B). In contrast, collagenase
reatment, which increased the lag time of thrombin formation
rastically from 20.5  2.1 min to 38.4  11.1 min after
ollagen stimulation (p  0.001) (Fig. 4C), had no influence
n the rate of thrombin formation with plaque stimulation
Fig. 4A; and data not shown). This indicates that only plaque
t Aggregation, Whereas Plaque TF Drives Coagulation
material with platelet glycoprotein VI (GPVI). Plaque was pretreated with collage-
l/l MgCl2 were added to citrated PRP before plaque (1.25 mg wet weight/ml
d coagulation but not aggregation is mediated by plaque TF in PRP. Plaque
ntibody (4 g) for 10 min at 37°C. The CaCl2 (12 mmol/l) and MgCl2 (0.1
ative tracing and bar diagram; p  0.003 as compared with IgG. (C) Plaque-
wn are representative impedance aggregation tracings after addition of plaque
l CTI and 8 mmol/l CaCl2 and 0.1 mmol/l MgCl2. Plaque or TF was pretreated
as in Figure 2.atele
plaque
mmo
-induce
ti-TF a
resent
. Sho
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iationsF but not platelet activation by collagenous plaque constitu-
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March 16, 2010:1147–58 Initial Steps of Atherothrombosisnts is critical for thrombin formation after exposure of PRP to
laque. In PFP, anti TF-antibody treatment of plaque entirely
bolished thrombin formation, whereas collagenase treatment
f plaques had no effect, indicating the specificity of these
reatments (data not shown). These results suggest that colla-
en matrix is not required to support the activity of TF. In
ddition, immunofluorescence microscopy of plaque homoge-
ates demonstrated no colocalization of TF with collagen
tructures (data not shown).
To corroborate the results from nephelometry and thrombin
eneration measurements, we also analyzed the clotting time in
PP and PRP as well as whole blood by using thrombelastog-
aphy (Rotem; Pentapharm). Plaque-induced coagulation in
PP, PRP, and whole blood after similar lag times: 9.2  4.4
in, 9.1  4.1 min, and 9.0  3.8 min, respectively (n  9
laques). Blockade of plaque TF by pre-incubating plaques
ith an anti-TF antibody drastically prolonged the plaque-
nduced clotting times in PRP and blood to 21 3.9 min and
8.0  3.2 min (n  10 for PRP; n  12 for blood),
espectively, close to control values in the absence of plaque.
Blood-borne TF did not play a role in plaque-stimulated
oagulation for the following reasons: the inhibition of plaque-
nduced clotting with the anti-TF antibody: 1) caused a similar
elay of clotting in PRP and blood; 2) depended on the
ncubation time of plaque with the anti-TF antibody; and
) did not occur when the anti-TF antibody was added directly
o the blood. Furthermore, we could not confirm a role of
Figure 4 Plaque-Induced Thrombin Formation Is Mediated by P
Whereas Collagen-Induced Thrombin Formation Is Dep
(A) Plaque-stimulated thrombin formation in platelet-free plasma (PFP) and PRP. In
thrombin formation in PFP and PRP. Inhibition by anti-TF antibody. (C) Collagen-stim
50 mmol/l TES, N-Tris[hydroxymethyl]methyl-2-amino-ethan-sulfonic acid, 0.36 mmlood-borne TF in collagen-stimulated clot formation as seported previously (26). In the presence of CTI to inhibit the
XII-dependent coagulation pathway, collagen used at a con-
entration (2.5 g/ml) that induced maximal platelet aggrega-
ion similar to plaques induced fibrin formation in blood only
fter a long lag time not different from control (data not
hown).
Together these results indicate that plaque TF and not
lood-borne TF is critical for fibrin formation after plaque
timulation of blood.
ffect of FXII inhibition on collagen-, plaque-, and
F-induced thrombin and fibrin formation. After
laque-induced stimulation of PRP and blood, thrombin
ight additionally be generated by the “intrinsic” FXII–
nitiated coagulation cascade. However, we observed that
nhibition of FXII with CTI, which delayed spontaneous
nd collagen-induced clotting in stirred PRP and whole
lood, had no significant effect on plaque-induced clotting
imes and platelet aggregation (Table 1, Fig. 2B).
Similarly, with collagen stimulation, CTI delayed the lag
ime of thrombin formation from 17.1  2.9 min to 26.4 
.4 min and the time to peak from 22.7  3.2 min to 32.2 
.2 min (n  3); this was not seen after plaque stimulation
data not shown).
inetics and mechanisms of atherothrombosis under
rterial blood flow conditions. On both, collagen- and
laque-coated surfaces, the kinetics of aggregation were
ndistinguishable beginning within the first minute after
TF,
nt on Factor XIIa Activation
n by anti-TF antibody: left, thrombogram; right, bar diagram. (B) TF-stimulated
d thrombin formation in PRP. Inhibition by CTI and collagenase. TESCA buffer 
Cl2; other abbreviations as in Figure 2.laque
ende
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Initial Steps of Atherothrombosis March 16, 2010:1147–58urther recruitment and aggregation of oncoming platelets
Fig. 5, Online Video 1) (data not shown). A firmly adherent
ayer of spread platelets at the bottom of the aggregates was
etectable 5 min after start of flow and gave a firm base against
etachment. On the contrary, on the TF-coated surface first
brin fibers formed, which were oriented parallel to the flow
irection, and only after this fibrin layer had formed, platelets
tarted to adhere and aggregate thereupon (Fig. 5G).
Once large platelet aggregates on the plaque-coated
urface were generated, fibrin fibers developed at the bottom
f the aggregates in flow niches and protruded from there
adially outward (Figs. 5C to 5E, Online Video 1). On
ollagen- and plaque-coated surfaces, fibrin polymerization
t the aggregates started 5 to 6 min after the beginning of
ow. No fibers were detectable in the aggregate-free areas of
he perfused surface. On TF (0.3 ng) coated surfaces, a
adial outgrowth of fibrin fibers at the bottom of the platelet
ggregates appeared as a second wave of fibrin formation 4
in after flow start (Fig. 5H).
Incubation of blood obtained from 5 different donors
ith the anti-GPVI antibody 10B12 inhibited plaque-
nduced platelet adhesion and aggregate formation on av-
rage by 78% after 5 min of blood flow. The degree of
nhibition varied between blood donors. In blood donor 3,
ven after 15 min, no platelet aggregates and hence no fibrin
ormation were observed after anti-GPVI antibody pre-
ncubation of blood (data not shown). In contrast, pretreat-
ent of plaques with anti-TF antibody showed no signifi-
ant effect on the time of platelet aggregate formation (data
ot shown) and on platelet aggregate coverage of the plaque
urface 3 and 5 min after start of flow (Fig. 6B, top). Fibrin
ormation time, however, was drastically prolonged in com-
arison with controls (Fig. 6B, bar diagram). After plaque
F inhibition, 2 of 5 plaques did not induce any fibrin fibers
TI Delays Collagen-Induced But Notlaqu -Induced Clotti g of PRP and BloodTable 1 CTI D lays Collagen-I uced But NotPlaque-Induced Clotting of PRP and Blood
Addition to Start of Clotting, min
Control CTI
None
Blood 7 2 (3) 18 3 (3)*
PRP 15 4 (4) 25*
Plaque
0.42† blood 3.8 1.3 (5) 4.9 0.7 (4)
0.83† blood — 3.4 1.2 (8)
1.23† blood 2.5 0.6 (3) 2.8 0.5 (3)
1.23† PRP 4.3 2.1 (6) 4.7 2.5 (6)
Collagen
0.5-g/ml blood — 10 (7)
2.5-g/ml blood 4.7 1.5 (7) 14.0 5.3 (6)*
2.5-g/ml PRP 5.9 1.1 (6) 16.3 5.3 (6)*
latelet-rich plasma (PRP) or blood was incubated with or without corn trypsin inhibitor (CTI) (32
g/ml). Calcium chloride (12 mmol/l in PRP, 8 mmol/l in blood) and magnesium chloride (0.1
mol/l) were added before the experiment. Clotting times were determined nephelometrically.
alues are mean  SD; number of experiments is in parentheses. *p  0.005 as compared with
ontrol; †numbers are milligrams plaque wet weight/ml final concentrations.5 min after start of flow. mInhibition of FXII did not change the kinetics of platelet
dhesion and aggregation or the size of aggregates on all 3
urface coatings, and on plaque and TF surfaces, CTI did
ot significantly change the lag time of fibrin formation. On
laque surfaces, fibrin was detected after 5.4  1.4 min
n  5) without CTI and after 6.2  1.2 min (n  3; p 
.05) with CTI. Only on collagen surfaces, CTI completely
revented fibrin formation: in the absence of CTI, fibrin
bers were detected after a delay of 5.6 0.4 min after start
f flow; in the presence of CTI fibrin formation could not
e detected on collagen up to 15 min after start of flow
n 5; p 0.003). These results under flow are concordant
ith the results under static conditions and indicate a purely
XII-dependent pathway for fibrin formed on collagen but
ot on plaque surfaces.
iscussion
ur study addressed the mechanism and kinetics of athero-
hrombosis after rupture of human atherosclerotic plaques.
nder static and under arterial flow conditions, plaque-
nduced thrombosis proceeded in 2 distinct steps. Collage-
ous plaque components rapidly (within the first minute)
nduced platelet adhesion and aggregation through activa-
ion of GPVI. Thrombin was not formed in this initial
hase and played no role in platelet activation. Only after a
elay of several minutes (under flow after 5 min) was
hrombin and fibrin formation observed, driven entirely by
laque TF. Fibrin fibers were observed only at sites where
latelet aggregates had formed. The key role of collagen/
PVI interaction in inducing atherothrombosis was dem-
nstrated by the drastic inhibition of plaque-induced
hrombus formation by blocking platelet GPVI. In contrast
nhibition of thrombin or plaque TF did not inhibit
laque-induced platelet adhesion and aggregation.
Our results of the early phase (first 15 min) of plaque-
nduced thrombus formation are in partial conflict with
arlier studies of Badimon et al. (27), who found that local
nhibition of plaque TF reduced deposition of both platelets
nd fibrin after 5 min of perfusion. In our study, plaque TF
as found to be critical only for fibrin formation but not for
latelet adhesion and aggregate formation. The discrepan-
ies between the earlier study and our own results are
xplained by several experimental differences: 1) the source
nd processing of human plaque material; 2) the type of
lood anticoagulation and perfusion model used; and 3) the
nalysis of thrombus formation. In short, we used fresh
ipid-rich carotid plaque material immediately frozen in
iquid nitrogen. The atheromatous plaque material contain-
ng the cap was gently homogenized, to expose all the
hrombogenic plaque components to the blood under static
nd defined shear conditions. It is likely that after plaque
upture (or after plaque damage by percutaneous coronary
ntervention) components of both the cap and core will be
xposed to circulating blood (1,2). Finally, thrombus for-
ation under flow was analyzed by microscopic real-time
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p
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March 16, 2010:1147–58 Initial Steps of Atherothrombosisisualization. In the former study, specimens of human
orta were obtained at necropsy; the tissue caps were
emoved from the atherosclerotic plaques, thereby possibly
liminating collagenous platelet-activating matrix compo-
ents; an extracorporeal method of perfusing heparinized
Figure 5 Platelet Adhesion, Aggregation, and Fibrin Formation
Citrated blood readjusted to physiological calcium (Ca2) and magnesium (Mg2)
(A to D) Images representative of 5 experiments. (A) Plaque homogenate at the b
aggregates; specific fluorescence in green. (C) Bottom view of platelet aggregate
microscopy [RICM], black region, arrowheads), and fibrin fibers emanating radially
atherosclerotic plaque and radially oriented fibrin fibers that predominate at the bo
material appear devoid of fibrin fibers. Large platelet aggregates on plaque (E) wit
plaque with an anti-TF antibody. (G) Fibrin fibers oriented parallel to flow streamlin
yet. (H) After platelets aggregate on the fibrin coating, then a second wave of radi
other abbreviations as in Figure 2.ig blood by an arteriovenous shunt was used; and end point teasurements (after 5 min) of deposition of 111In-labeled
latelets and 123I-labeled fibrinogen were performed.
On collagen, we found that coagulation was activated
hrough the intrinsic (factor XIIa) pathway, confirming
revious and recent studies (28–30). In contrast, coagula-
wing Blood Exposed to Plaque and TF
trations was perfused over plaque or TF coatings at a shear rate of 1,500 s1.
ng of blood flow, yellow autofluorescence. (B) Plaques with attached platelet
ed to plaque demonstrating spread platelets (reflection interference contrast
aggregate (arrows). (D) Scanning electron micrograph of platelet aggregate on
f the aggregate. Of note, regions of the glass surface not coated with plaque
l outgrowth of fibrin fibers and (F) without fibrin formation after pretreatment of
ed on TF coated surface after initiation of blood flow; no platelets are adherent
n outgrowth occurs at the base of aggregates. BF  bright field microscopy;of Flo
concen
eginni
attach
from
ttom o
h radia
es form
al fibriion induced by plaques was entirely driven by the TF-
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Initial Steps of Atherothrombosis March 16, 2010:1147–58Figure 6 Effect of Anti-GPVI Antibody Incubation of Blood and Anti-TF Antibody Pretreatment of
Plaque on Platelet Aggregation and Fibrin Formation of Flowing Blood Exposed to Plaque
Citrate blood readjusted to physiological Ca2 and Mg2 concentrations was perfused over plaque-coated surfaces for 15 min at 37°C with a shear rate of 1,500 s1. Plaque
pooled from different patients was used. (A) Blood was pretreated with the anti-GPVI antibody 10B12 or control antibody. Representative flow images 5 min after start of flow;
plaque material is visualized by autofluorescence (light-grey), platelets by mepacrine fluorescence (white; ). Bar: 50 m; below, bar diagram, results of experiments with 5
blood donors. (B) Plaque was pretreated with anti-TF antibody or rabbit IgG; left, platelet coverage 3 and 5 min after start of flow; platelets; o, plaque. Right, bar diagram of
the effects of anti-TF antibody or rabbit IgG on platelet aggregate formation 5 min after start of flow (left) and on fibrin formation time; values are mean  SD (n  5 with
plaques of different patients and blood of different donors). p  0.003 treatment versus control. Abbreviations as in Figure 2, 3, and 6.
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March 16, 2010:1147–58 Initial Steps of Atherothrombosisriggered extrinsic pathway and overrode the factor XII acti-
ation, resulting in fibrin formation several minutes before the
ollagenous matrix or other plaque components could become
perative via the intrinsic pathway. This is further corroborated
y previous results, which showed that fibrin formation on
F-expressing cellular surfaces is initiated by TF/factor VIIa–
ependent direct activation of factor X, whereas on collagen
urface this occurs via the intrinsic pathway (31).
Although TF is accepted as the primary initiator of
oagulation, plaque TF exposure alone does not determine
hether or not clotting will occur under flow. Our results
nder flow conditions show fibrin formation only subse-
uent to plaque-induced platelet activation and no fibrin-
ormation in the absence of platelets (data not shown). This
s in agreement with the current model of coagulation
eparating an initiation and a propagation phase of throm-
in formation on activated platelets. Thus, plaque TF
xpression combined with support of prothrombinase as-
embly on activated platelets is much more efficient in
nitiating coagulation than TF alone (32). Platelets provide
he surface on which most of the thrombin required for clot
ormation is generated, and coagulation proceeds when TF
s brought into close proximity to activated platelets. This
ould explain why we observed fibrin fibers radiating from
latelet aggregates.
The unaltered platelet adhesion and aggregation on
F-blocked plaque indicates that thrombin generated by
laque TF is not involved in these platelet responses. Under
either static nor arterial flow conditions did thrombin,
hich was formed later by plaque TF activity, play a role in
he early phase of plaque-induced platelet adhesion and
ggregate formation. Thrombin, however, might be impor-
ant in the later phase of plaque-induced thrombosis and, by
nducing platelet secretion and phosphatidylserine exposure,
rovide a pro-coagulant platelet surface helping in the
ssembly and activation of clotting factors.
The orientation of fibrin fibers polymerizing in flow
losely follows the direction of adjacent flow streamlines
ven in complex 3-dimensional flow geometry (33). The
adial fiber orientation at the bottom of the platelet aggre-
ates indicated flow niches of almost zero flow (an optimal
ondition for fibrin polymerization) adjacent to the high
hear regions outside the aggregates, as can be clearly seen
y the movement of red cells (Online Video 1). In addition,
n the TF-coated surface the second wave of aggregate-
ostered fibrin formation suggests a role for phosphatidyl-
erine exposure on the surface of activated platelets (34). In
n ex vivo flow model over collagen it was shown that
dherent platelets formed the nuclei for fibrin fiber forma-
ion and that large platelet thrombi contained immunode-
ectable fibrin solely at the thrombus base (35).
Recent studies in mice indicate an important role for
blood-borne” TF in arterial thrombus formation after
ascular injury in vivo (36). Blood-borne TF is membrane
ound on microparticles from various cellular origins (36)
nd is also thought to enhance thrombosis after plaque
wupture (37). Our results clearly show that plaque TF and
ot blood-borne TF determines plaque-induced coagula-
ion. However, our study was carried out with blood from
ealthy volunteers, and the situation could be different in
ardiovascular patients with risk factors (smoking, diabetes,
ypercholesterolemia) having higher blood thrombogenicity
erhaps due to circulating TF. This possibility cannot be
xcluded. However, at present, it is not clear whether active
F is present or not in blood (38).
Current optimal treatment of patients with acute arterial
hrombosis requires a combination of anticoagulants and
ntiplatelet agents. The most serious adverse effect of this
ombined antithrombotic therapy is bleeding, which can
ounteract the beneficial therapeutic effect (8). Moreover,
he antiplatelet drugs currently available (aspirin, P2Y12
ntagonists) do not effectively inhibit plaque-induced plate-
et activation under arterial flow conditions (18). Our recent
tudy shows that binding of von Willebrand factor to
latelet glycoprotein Ib is critical for plaque-induced platelet
dhesion and aggregate formation under arterial flow con-
itions (1,500/s), giving further support to target glyco-
rotein Ib as novel antithrombotic strategy (11,18,39).
ngoing clinical trials in patients with atherothrombosis
arget according to the present study the 2nd step of
laque-induced thrombus formation: factor Xa inhibitors,
ral thrombin inhibitors, and thrombin receptor (protease-
ctivated receptor) antagonists. The results of the rivaroxa-
an (factor Xa inhibitor) dose-finding study in patients with
cute coronary syndrome show that the combination of
nticoagulants in high dose with dual platelet inhibition
rastically increases the bleeding risk without showing
ajor clinical benefit (40).
tudy limitation. This is an ex vivo study exposing ho-
ogenates of human atheromatous plaques to blood of
ealthy persons and not an in vivo study after plaque rupture
f cardiovascular patients.
onclusions
ur finding that thrombi develop sequentially on athero-
clerotic plaques in arterial flow—first, GPVI-dependent
latelet activation; and second, plaque TF-mediated fibrin
ormation in flow niches provided by the growing platelet
ggregates—implies that the first GPVI-dependent step
ould be a promising therapeutic target for the prevention of
therothrombosis after plaque rupture. Notably, animal
xperiments have shown that the bleeding time was only
oderately increased after depletion of platelet GPVI (41).
n contrast, a strategy directed to inhibit TF in plaque or
lood, or FXIIa is not supported by the present study.
eprint requests and correspondence: Dr. Wolfgang Siess,
nstitute for Prevention of Cardiovascular Diseases, University of
unich, Pettenkoferstrasse 9, 80336 Munich, Germany. E-mail:
siess@med.uni-muenchen.de.
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